



California Notice 2024-19

To: Pesticide Registrants and Other Stakeholders

Subject: SEMIANNUAL REPORT SUMMARIZING THE REEVALUATION STATUS OF PESTICIDE PRODUCTS DURING THE PERIOD OF January 1, 2024, THROUGH June 30, 2024

California regulations require the Department of Pesticide Regulation (DPR) to investigate all reports of adverse effects to public health or the environment that indicate a pesticide may have caused or is likely to cause a significant adverse impact. Reevaluation of a registered pesticide is required if from the investigation a significant adverse impact occurred, or is likely to occur, from its use.

Title 3 of the California Code of Regulations (3 CCR) section 6221, specifies several factors under which DPR may initiate a reevaluation: (a) public or worker health hazard, (b) environmental contamination, (c) residue over tolerance, (d) fish or wildlife hazard, (e) lack of efficacy, (f) undesirable phytotoxicity, (g) hazardous packaging, (h) inadequate labeling, (i) disruption of the implementation or conduct of pest management, (j) other information suggesting a significant adverse effect, (k) availability of an effective and feasible alternative material or procedure that is demonstrably less destructive to the environment, and (l) discovery that data upon which a registration was issued is false, misleading, or incomplete. An ongoing DPR pesticide review may trigger a reevaluation. Reevaluation triggers also include data or information received from registrants, state and county pesticide use surveillance and illness investigations, pesticide residue sample analyses, environmental monitoring activities, and issues that may concern other state or federal agencies.

When a pesticide enters the reevaluation process, DPR reviews existing data and may require that registrants provide additional data to characterize the nature and extent of the potential hazard and identify appropriate mitigation measures if needed.

DPR concludes reevaluations in several different ways. If data shows no significant adverse effect, DPR concludes the reevaluation without additional restrictions on use or other regulatory actions. If new restrictions are necessary, DPR places controls on the pesticide to mitigate the potential significant adverse effect. If the adverse impact cannot be mitigated, DPR cancels or suspends the registration of pesticide products meeting applicable legal standards. This report complies with the requirement of 3 CCR section 6225, which requires DPR to prepare a semiannual report describing pesticides reevaluated, under reevaluation, or for which factual or scientific information was received, but no reevaluation was initiated.

The report contains two sections:

- I. *Formal Reevaluations*—initiated when an investigation indicates a significant adverse impact has occurred or is likely to occur; and,
- II. *Preliminary Investigations (Evaluations)*—initiated when DPR receives possible adverse impact data or information resulting from the use of a product and/or active ingredient, but no formal reevaluation has been initiated.

CALIFORNIA NOTICE 2018-01

[California Notice 2018-01](https://cdpr.ca.gov/docs/registration/canot/2018/ca2018-01.pdf) (Notice), titled *Expanded Use of Pesticide Products Under Reevaluation* <cdpr.ca.gov/docs/registration/canot/2018/ca2018-01.pdf>, was issued in January 2018. In accordance with this notice, DPR will not act upon an Application for Pesticide Registration or an Application to Amend Pesticide Product if it's relevant to the concern that prompted the reevaluation. The notice affects new products, supplemental distributor registrations, amendments, Special Local Needs, and Experimental Use Permits. DPR will evaluate Emergency Exemption requests on a case-by-case basis if a pest management or public health need arises. When DPR completes the reevaluation, DPR will be able to, in light of the reevaluation determination, consider the Application for Pesticide Registration or Application to Amend Pesticide Product.

Assembly Bill 2113

On July 2, 2024, the Governor signed Assembly Bill (AB) 2113 which, among other changes, added section 12824.5 to the Food and Agricultural Code (FAC). FAC section 12824.5 requires DPR to post on its internet website, on or before January 1, 2025, estimated completion times for pesticides undergoing reevaluation as of January 1, 2024.

FORMAL REEVALUATION

DPR initiates formal reevaluation when an investigation indicates a significant adverse impact has occurred or is likely to occur. Each reevaluation is summarized with regard to the following four areas: (1) Basis and Scope, (2) Data Requirements (if any), (3) Summary of Scientific Evaluation (e.g., protocol development, study/data submission and evaluation, DPR analysis papers, risk assessments) and Related Legislation (if necessary), and (4) Mitigation Efforts and Status (if any).

CHLOROPICRIN – 30 Products

Basis and Scope

In October 2001, DPR placed pesticide products containing the active ingredient chloropicrin

into reevaluation. The reevaluation is based on air monitoring data, which found that air concentrations at some distances from treated greenhouses exceeded the National Institute for Occupational Safety and Health reference exposure limit and the Occupational Safety and Health Administration permissible exposure limit of 100 parts per billion (ppb), averaged over an eight-hour period. In addition, DPR found that data submitted under the Birth Defects Prevention Act indicated a potential for chloropicrin to cause adverse health effects at low doses.

Data Requirements

Under this reevaluation, DPR required chloropicrin registrants to conduct and submit data on various worker exposure and air quality monitoring studies from field and greenhouse applications. In August 2005, DPR completed review of required monitoring data and began a risk assessment of chloropicrin uses as part of the reevaluation process to mitigate potential adverse effects at low concentrations. In January 2015, DPR notified chloropicrin registrants of a data requirement to determine if chronic exposure to chloropicrin presents a carcinogenic hazard requiring mitigation. In July 2015, DPR established a mechanistic study data requirement to assess the carcinogenic hazard of chloropicrin. In August 2023, DPR required chloropicrin registrants to conduct five additional studies to more precisely evaluate chloropicrin's mutagenic potential.

Summary of Scientific Evaluation

The required mechanistic study was initially divided into three phases. In June 2016, DPR accepted the protocol for the Phase 1 mechanistic study titled, *Identification of mouse lung target cell type and target respiratory region for effects following nose-only inhalation exposure to chloropicrin vapor*. Due to several unforeseen circumstances and COVID-19 related delays, the Chloropicrin Task Force (CMTF) submitted the Phase 1 study results in September 2022, and final nasal tissue analysis in January 2023.

After review, DPR scientists determined that the two remaining study phases will not generate the data needed to determine if chloropicrin works by a mutagenic mode of action and if the mouse model for lung tumors is relevant in humans. DPR scientists evaluated the adverse outcome pathways for the formation of lung tumors in animal models and the most current literature and methodologies for evaluating mutagenesis. Throughout 2023, DPR met with CMTF to discuss proposed alternative studies using in vivo and in vitro techniques that would more quickly provide data to clarify chloropicrin's mode of action and mutagenic potential and if the mouse model for lung tumors is relevant for humans.

In August 2023, DPR required chloropicrin registrants to submit protocols for five studies: (1) *In vivo* mutagenesis following mouse inhalation exposure using error-corrected next-generation sequencing (ecNGS); (2) Regenerative proliferation following inhalation exposure, including both single (6 hour) and repeated (6 hour per day for 5 sequential days) exposure;

(3) *Ex vivo* DNA adduct; (4) Test if inhibitors of CYP isoforms block cytotoxicity in mice; (5) Evaluate human relevance using CYP2F2-null and humanized (CYP2F1) mice if results from Study 4 are positive. CMTF began submitting draft protocols for the studies in October 2023. CMTF began work on the first study in early December 2023. In June 2024, CMTF submitted a progress report on Study 1. Due to a laboratory closure, CMTF needed to switch to a different laboratory to conduct the second half of Study 1. Progress reports and study results are expected to be submitted to DPR throughout 2024 and 2025.

Mitigation Efforts and Status

In February 2010, DPR completed a risk characterization document (RCD) for chloropicrin as a toxic air contaminant (TAC). The RCD analyzed the risks associated with potential exposures to residents and bystanders from ambient and offsite air concentrations of agricultural use chloropicrin products. Effective January 2011, DPR established by regulation chloropicrin as a TAC and initiated development of use restrictions following TAC procedures specified in state law. In November 2012, DPR completed its comprehensive RCD for chloropicrin, which included dietary and occupational exposure scenarios.

In May 2013, DPR proposed mitigation measures designed to protect bystanders and residents from acute exposures to chloropicrin for public comment. DPR proposed additional restrictions to protect residents and bystanders by including additional buffer zones, restrictions on buffer zone credits, acreage limits, time periods between applications with overlapping buffer zones, emergency preparedness and response, and notice of intent requirements. In January 2015, DPR issued “Control Measures for Chloropicrin: Control of Resident and Bystander Acute Exposure from Soil Fumigation Applications.” The controls are intended to reduce risk from acute exposures to residents and bystanders that might occur near fields fumigated with products containing chloropicrin. In April 2015, DPR issued interim recommended restricted material permit conditions for field fumigants containing chloropicrin. In February 2017, DPR issued revised interim permit conditions developed to mitigate hazards of offsite movement of field fumigation applications of chloropicrin.

In March 2020, U.S. Environmental Protection Agency (U.S. EPA) issued its interim registration review decision for chloropicrin products. The interim decision includes labeling changes such as general updates to the glove statement, clarification on shade houses, soil sealing, and application rates on the product label. DPR accepted the first amended product labels with this new federal language in late 2021. These federal revisions address separate issues from the scope of California reevaluation. DPR continues to monitor amended pesticide product registrations to ensure labeling compliance.

For information on human health risk assessment and mitigation for chloropicrin, visit [Chloropicrin - Human Health Risk Assessment and Mitigation Documents and Activities](https://cdpr.ca.gov/docs/whs/active_ingredient/chloropicrin.htm) <cdpr.ca.gov/docs/whs/active_ingredient/chloropicrin.htm>.

CYFLUTHRIN - 16 Products

Basis and Scope

In May 1998, DPR placed pesticide products containing the active ingredient cyfluthrin into reevaluation. The reevaluation is based on DPR's investigations of a May 1997 respiratory irritation outbreak reported among orange harvesters exposed to cyfluthrin residues and other related pesticide illness reports. As part of the investigation, DPR's Worker Health and Safety Branch conducted two separate inhalation-monitoring studies in orange groves during orange harvest. As dust and pollen are a part of the normal working environment, DPR determined that additional variables in the work environment led to the workers' respiratory irritation symptoms. DPR compiled the results in its monitoring study titled, *Health and Safety Report HS – 1765*, which found a probability that cyfluthrin, applied close to harvest, led to the symptoms experienced.

Data Requirements

Under this reevaluation, DPR required registrants of pesticide products containing the active ingredient cyfluthrin to provide: (1) a respiratory irritation study, (2) a worker exposure study, and (3) monitoring data for structural applications. In October 2001, the primary manufacturer submitted two worker exposure studies regarding hand harvesting of oranges and sweet corn, four indoor exposures studies, and a study titled, *Study on the RD₅₀ Determination in Rats*. Based on this data, DPR determined structural monitoring data was no longer required. In February 2002, DPR required a worker exposure study during the harvesting of sweet corn. The results of the study were submitted to DPR in October 2004.

Summary of Scientific Evaluation

In 2006, DPR determined a comprehensive exposure assessment was necessary for cyfluthrin. In September 2008, DPR completed a cyfluthrin Exposure Scoping Document intended to lay the groundwork for the risk assessment process. DPR completed its review of the cyfluthrin sweet corn hand harvester studies. In August 2015, DPR completed a Summary of Toxicology Data document for chronic health effects on cyfluthrin.

Mitigation Efforts and Status

In January 2018, DPR issued a problem formulation document (PFD) to initiate risk assessment. In February 2018, DPR presented the PFD and initiation of the risk assessment for cyfluthrin to the Pesticide Registration Evaluation Committee (PREC). U.S. EPA completed its registration review and released the draft human health risk assessment in May 2020 and the interim registration review decision in September 2020. In March 2021, U.S. EPA revised the Agency's interim registration review decision. DPR continues to review and monitor federal decisions on

cyfluthrin pesticide product registrations. If upon completion of the RCD, DPR concludes that use of cyfluthrin poses a significant risk to workers, DPR will proceed with mitigation.

For information on human health risk assessment for cyfluthrin, visit [Cyfluthrin and Beta-Cyfluthrin - Human Health Risk Assessment and Mitigation Documents and Activities](https://cdpr.ca.gov/docs/whs/active_ingredient/cyfluthrin.htm) <cdpr.ca.gov/docs/whs/active_ingredient/cyfluthrin.htm>.

DIPHACINONE – 56 Products

Basis and Scope:

Pesticide products containing the active ingredients diphacinone and diphacinone sodium salt (henceforth collectively referred to as diphacinone) are classified as a first-generation anticoagulant rodenticide (FGAR). While both diphacinone and its sodium salt start as different chemical compounds, diphacinone sodium salt quickly converts to diphacinone in the environment. These products are registered for rodent control use. In target rodents, death is usually delayed by several days after direct consumption of a lethal dose. Non-target wildlife may be exposed by direct consumption of diphacinone or when they consume target rodents that have fed on diphacinone (indirect consumption).

DPR's 2023 Notice of Proposed Decision to Begin Reevaluation on diphacinone concluded that there have been substantial increases in diphacinone exposure rates to non-target wildlife, as represented in the California Department of Fish and Wildlife (CDFW) loss reports. These increases are concerning given the toxicity of diphacinone to mammals and birds, and potential to bioaccumulate. This, along with increases in sales and use data of diphacinone in recent years, suggests that there are increasing amounts of diphacinone in California's environment, which demonstrates that a significant adverse impact to non-target wildlife has occurred or is likely to occur.

In May 2023, DPR published [California Notice 2023-06](https://cdpr.ca.gov/docs/registration/canot/2023/ca2023-06.pdf) (Notice), titled *Notice of Proposed Decision to Begin Reevaluation of Diphacinone and Public Report* <cdpr.ca.gov/docs/registration/canot/2023/ca2023-06.pdf>, outlining the basis for this proposed reevaluation. In June 2023, DPR staff presented at the PREC meeting on this proposed action.

Following the closure of the public comment period, on October 3, 2023, DPR issued a Notice of Final Decision to Begin Reevaluation of diphacinone in [California Notice 2023-11](https://cdpr.ca.gov/docs/registration/canot/2023/ca2023-11.pdf) (Notice), titled *Notice of Final Decision to Begin Reevaluation of Diphacinone* <cdpr.ca.gov/docs/registration/canot/2023/ca2023-11.pdf>. This notice included response to significant comments received during the public comment period.

Data Requirements

Under this reevaluation, DPR required registrants of diphacinone pesticide products to: (1)

submit compliance proposals by December 2023 and identify relevant data, and (2) submit identified data by January 2024. All registrants of diphacinone products have complied with these requirements.

In June 2022, DPR contracted with Dr. Niamh Quinn, University of California Agriculture and Natural Resources, through 2024 to monitor for anticoagulant rodenticides (ARs) in urban carnivores (#21-C0091). This study and its results may provide general information to DPR on ARs. DPR granted a contract extension to allow sample processing to be completed. A final report is expected by June 2025.

Summary of Scientific Evaluation

DPR staff are currently considering all diphacinone data submitted and on file to determine if further use restrictions are necessary to address significant adverse effects to non-target wildlife.

Mitigation Efforts and Status

In 2024, DPR held meetings with CDFW to discuss potential mitigation measures in adherence to consultation requirements of Assembly Bill (AB) 1322 (see the “Related Legislation” section below). DPR continues to refine potential mitigation options and consider if further use restrictions are necessary to protect non-target wildlife.

Related Legislation

On October 13, 2023, Governor Newsom signed AB 1322 (Chapter 836, Statutes of 2023), which amended FAC section 12978.7. The amendments prohibit certain uses of diphacinone, a first-generation anticoagulant, due to their threat to mountain lions and other wildlife. This bill also establishes the standards, including concluding the diphacinone reevaluation, that are necessary to remove the prohibition. Effective January 1, 2024, most uses of rodenticides containing diphacinone are prohibited and required to be sold by licensed dealers. This prohibition will remain in effect until the DPR’s Director certifies completion of the diphacinone reevaluation and DPR’s development, in concurrence and consultation with the CDFW, and adoption of any additional use restrictions necessary to protect wildlife.

Although FAC 12978.7 generally prohibits use of diphacinone, there are limited exemptions for specified activities, such as agriculture, and use in locations necessary for public health and safety. Federal and State laws and regulations applicable to allowed uses must continue to be followed. Guidance on permitted uses of diphacinone under AB 1322 is available on DPR’s Enforcement Branch Web page titled [2023 Enforcement Branch Letters \(ca.gov\)](https://cdpr.ca.gov/docs/county/cacltrs/penfltrs/penf2023/2023menu.htm) <cdpr.ca.gov/docs/county/cacltrs/penfltrs/penf2023/2023menu.htm>.

For the full bill text please visit: [AB-1322 Pesticides: second-generation anticoagulant rodenticide: diphacinone](#).

<leginfo.legislature.ca.gov/faces/billTextClient.xhtml?bill_id=202320240AB1322#91CHP>

NEONICOTINOIDS (Non-agricultural Uses on Non-production Outdoor Ornamental Plants, Trees, or Turf) – 146 Products

Basis and Scope

On January 1, 2024, AB 363 amended FAC section 12838.

FAC section 12838(c)(3)(B) states that on or before July 1, 2024, the department shall initiate a reevaluation of neonicotinoid pesticides (containing the active ingredients imidacloprid, thiamethoxam, dinotefuran, clothianidin, and acetamiprid) for non-production agricultural outdoor uses on ornamental plants, trees, or turf for potential impacts on pollinating insects, aquatic organisms, and human health, taking into account relevant routes of exposure. On March 7, 2024, DPR released [CA Notice 2024-05](http://cdpr.ca.gov/docs/registration/canot/2024/ca2024-05.pdf) <cdpr.ca.gov/docs/registration/canot/2024/ca2024-05.pdf>, noticing the initiation of the reevaluation mandated by AB 363.

Data Requirements

To date, DPR has not required data for this reevaluation. DPR evaluators are currently reviewing data on file to determine if additional data are needed. If data are required, DPR will reach out to registrants with products included in the reevaluation.

Summary of Scientific Evaluation

A human health draft Risk Characterization Document (RCD) and Exposure Assessment Document (EAD) for use of imidacloprid was submitted to U.S. EPA and Office of Environmental Health Hazard Assessment (OEHHA) for scientific review in March 2024. Finalized documents that incorporate this scientific review will be released in 2025. In addition, draft risk and exposure assessments for thiamethoxam, dinotefuran, clothianidin, and acetamiprid will be submitted to U.S. EPA and OEHHA for scientific review in 2025.

Related Legislation

On October 8, 2023, Governor Gavin Newsom signed into effect AB 363 (Chapter 520, Statutes of 2023) which added amended FAC section 12838. The statute prohibits the sale, possession, or use of non-agricultural neonicotinoid products with uses on non-production ornamental plants, trees, or turf by non-licensed applicators effective January 1, 2025. The statute also requires DPR to evaluate the potential impacts of neonicotinoid pesticides labeled for use on non-production outdoor ornamental plants, trees, and turf for potential impacts on pollinating insects, aquatic

organisms, and human health. DPR must provide a determination by July 1, 2027, and adopt any necessary control measures by July 1, 2029. For the full bill text please visit: [AB-363 Pesticides: neonicotinoids for nonagricultural use: reevaluation: control measures](https://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=202320240AB36) <leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=202320240AB36>.

NITROGUANADINE NEONICOTINOIDS – 181 Products

In February 2009, DPR placed certain outdoor use pesticide products containing the active ingredients imidacloprid, thiamethoxam, clothianidin, and dinotefuran into reevaluation. The reevaluation was based on an adverse effects disclosure involving the active ingredient imidacloprid. DPR's evaluation of the adverse effects data noted two critical findings: (1) high levels of imidacloprid in leaves and blossoms of treated plants, and (2) increases in residue levels over time. Thiamethoxam, dinotefuran, and clothianidin are in the same chemical family as imidacloprid, known as the nitroguanidine insecticide class of neonicotinoids, and have similar properties and characteristics (e.g., soil mobility, half-lives, and toxicity to honey bees).

Data Requirements

Under this reevaluation, DPR required registrants of pesticide products containing the active ingredients imidacloprid, thiamethoxam, clothianidin, and dinotefuran (collectively referred to as nitroguanidine neonicotinoids) to provide the following data for each active ingredient: (1) LC₅₀ (acute) toxicity study, on honey bees, starting at the larval stage through emergence; and (2) field-based residue studies in pollen, nectar, and leaves from specific agricultural orchard and row crops. For field-based residue data requirements, DPR used its Pesticide Use Reporting database to determine the crops of focus for each active ingredient. DPR determined that initial field residue studies were inconclusive and did not involve "worst-case" scenarios (i.e., a residue study conducted at the permitted California maximum application rate and the minimum reapplication interval). DPR modified its residue study strategy to require controlled applications at the highest maximum application rate per year for two consecutive years. DPR required neonicotinoid registrants to conduct these two-year prescriptive residue studies for certain commodities.

Additionally, U.S. EPA required honey bee toxicity studies and additional field-based residue studies for their reevaluation of neonicotinoids, which were shared with DPR and the Health Canada Pest Regulatory Management Agency (PRMA).

Summary of Scientific Evaluation

In September 2009, DPR notified neonicotinoid registrants of the LC₅₀ and field residue study data requirements. DPR received all required data by 2018. The data was evaluated and DPR issued a risk determination in July 2018. See more information below on this report.

Mitigation Efforts and Status

Between 2010 and 2012, imidacloprid and thiamethoxam registrants, respectively, agreed to remove almond use from all California product labels. DPR considered this an important step in pollinator protection since almond orchards require a large number of pollinators.

In July 2018, DPR issued the California Neonicotinoid Risk Determination and submitted it to the State Legislature in accordance with the requirements of FAC section 12838. Shortly after, DPR incorporated newly available information and issued an addendum to the California Neonicotinoid Risk Determination in January 2019. The Risk Determination and Addendum compares colony feeding study values to worst-case scenario residue values to determine risks to honey bees. In 2020, DPR received a formal scientific peer review on the Risk Determination and Addendum and incorporated feedback into the mitigation efforts.

In accordance with the requirement of FAC section 12838 for DPR to adopt necessary control measures to protect pollinator health, DPR continued to review data and consult with experts and other stakeholders to help inform potential mitigation decisions. DPR developed several mitigation options and contracted with the California Department of Food and Agriculture (CDFA) to provide an economic analysis of the various options. CDFA provided economic analysis reports to DPR in August 2019, July 2020, and July 2021, as DPR explored mitigation options and revised the proposed regulations.

On April 12, 2023, The Office of Administrative Law approved the adoption of 3 CCR sections 6990 through 6990.16 as control measures necessary to protect pollinator health as identified in the 2018 California Neonicotinoid Risk Determination and Addendum. The regulations became effective on January 1, 2024. Pesticide applicators must review and comply with the regulations. Neonicotinoid product labels will not be updated with these requirements.

In the fall of 2023, DPR issued guidance to registrants and applicators regarding the regulations that became effective on January 1, 2024. The guidance included customized fact sheets for each affected crop group, details regarding what the new regulations are, why they were put into place, when they come into effect, who they apply to, and how applicators can comply with the new regulations. The fact sheets were also translated into Spanish for transparency. More information about the regulations, including crop-specific fact sheets, can be found here: [Neonicotinoid Regulations](https://cdpr.ca.gov/docs/enforce/neonicotinoid/neonicotinoid_regulations.htm) <cdpr.ca.gov/docs/enforce/neonicotinoid/neonicotinoid_regulations.htm>. Additional guidance on the interpretation of "Bloom" can be found here: [Interpretation of Bloom](https://cdpr.ca.gov/docs/county/cacltrs/penfltrs/penf2023/202318.htm) <cdpr.ca.gov/docs/county/cacltrs/penfltrs/penf2023/202318.htm>.

On March 7, 2024, with [California Notice 2024-04](https://cdpr.ca.gov/docs/registration/canot/2024/ca2024-04.pdf) <cdpr.ca.gov/docs/registration/canot/2024/ca2024-04.pdf>, DPR concluded the neonicotinoid reevaluation of nitroguanidine neonicotinoid insecticides. We simultaneously opened a new neonicotinoid reevaluation on non-agricultural

non-production outdoor ornamental plants, trees, and turf. Please see the section above for more details.

SECOND-GENERATION ANTICOAGULANT RODENTICIDES (SGARs) – 64 Products *Basis and Scope*

Second-generation anticoagulant rodenticide (SGAR) products are those that contain the active ingredients brodifacoum, bromadiolone, difenacoum, and difethialone (collectively referred to as SGARs). DPR conducted a preliminary investigation of unpublished wildlife incident data and mortality data and public literature submitted by CDFW and other sources on anticoagulant rodenticides and prepared a report on its findings.

Based on the investigation, the Director found that a significant adverse impact has occurred or is likely to occur to non-target wildlife from the use of SGARs and proposed to begin reevaluation. In November 2018, DPR issued its proposed decision to begin reevaluation for SGAR products for public comment. On March 12, 2019, DPR issued its final decision to begin reevaluation for SGAR products.

Data Requirements

Under this reevaluation, DPR required registrants of SGAR pesticide products to: (1) submit compliance proposals by May 2019, and (2) submit existing data related to non-target wildlife exposure by June 2019. Registrants of brodifacoum, bromadiolone, and difethialone products complied with these timelines. However, in place of submitting compliance proposals and data, difenacoum registrants submitted voluntary cancellations for all registered difenacoum products. As of May 2019, DPR no longer has any difenacoum products registered for use in California.

In August 2020, DPR asked companies to identify efficacy data that could inform mitigation by demonstrating a lower concentration of active ingredient in the target pests, such as through reduced application rates, lowered concentration of the active ingredient, and alternative bait timings. By November 2020, companies either submitted new data to DPR or identified relevant studies for review from previous submissions. DPR scientists have completed their initial review of company identified data, data on file, and public literature.

In 2020, DPR contracted with Dr. Niamh Quinn, University of California Agriculture and Natural Resources, to conduct a study on rodenticide Best Management Practices (#19-C0061). DPR authorized the researcher under Food and Agricultural Code (FAC) section 12978.7, and a final report was submitted. DPR's conditional authorization of additional research by Dr. Quinn's ended July 2023.

In June 2022, DPR contracted with Dr. Niamh Quinn, University of California Agriculture and Natural Resources, through 2024 to monitor for ARs in urban carnivores (#21-C0091). This study and its results may provide general information to DPR on ARs. DPR granted a contract

extension to allow sample processing to be completed. A final report is expected by June 2025.

Mitigation Efforts and Status

In November 2022, U.S. EPA issued their proposed interim decision (PID) for anticoagulant rodenticides which included all SGARs. Additionally in 2022, DPR completed review of data on file. DPR continues to review and monitor federal decisions on SGAR pesticide product registrations. DPR continues to work with SGAR registrants, the Rodenticide Task Force, interested stakeholders, researchers, and federal counterparts to discuss potential mitigation strategies and any proposed actions on anticoagulant rodenticides.

Throughout 2023, DPR met with and solicited feedback from Pest Control Operators, non-governmental organizations, California Department of Public Health, CDFA, and CDFW to discuss potential mitigation measures. DPR and CDFW continue to meet yearly under current legislation. DPR continues to refine potential mitigation options and consider if further use restrictions are necessary to protect non-target wildlife.

Related Legislation

On October 13, 2023, Governor Gavin Newsom signed AB 1322 which amended FAC section 12978.7. This amendment prohibits the use of diphacinone, a first-generation rodenticide, and second-generation rodenticides in the state and wildlife areas unless certified by the DPR's director. This amendment authorizes restrictions to include a requirement to implement alternatives, such as integrated pest management, before use of diphacinone and SGARs. Federal and State laws and regulations applicable to allowed uses must continue to be followed. Guidance on permitted uses of SGARs under AB 1322 is available on DPR's Enforcement Branch Web page titled [2023 Enforcement Branch Letters \(ca.gov\)](https://cdpr.ca.gov/docs/county/cacltrs/penfltrs/penf2023/2023menu.htm) <cdpr.ca.gov/docs/county/cacltrs/penfltrs/penf2023/2023menu.htm>.

For the full bill text please visit: [AB-1322 Pesticides: second-generation anticoagulant rodenticide: diphacinone](https://leginfo.ca.gov/faces/billTextClient.xhtml?bill_id=202320240AB1322#91CHP).
<leginfo.ca.gov/faces/billTextClient.xhtml?bill_id=202320240AB1322#91CHP>

For more information on the reevaluation for SGARs visit [Second-Generation Anticoagulant Rodenticides \(SGARs\)](https://cdpr.ca.gov/docs/registration/reevaluation/chemicals/sgars.htm) <cdpr.ca.gov/docs/registration/reevaluation/chemicals/sgars.htm>

PRELIMINARY INVESTIGATIONS (EVALUATIONS)

DPR conducts preliminary investigations of products (and active ingredients) for which the Department, or other State or county agencies, have identified possible hazards. As a result of evaluation, the investigation may lead to formal reevaluation.

PARAQUAT DICHLORIDE – 7 Products

Basis and Scope:

Pesticide products containing the active ingredient paraquat dichloride are registered in California for use as an herbicide and defoliant on a variety of agricultural plants. Paraquat dichloride is a California restricted material, and therefore not available for homeowner use and no products are registered for application in residential areas. In response to [California Notice 2022-18](#) (Notice), titled *Notice of Proposed Decision to Renew Pesticide Product Registrations for 2023* <cdpr.ca.gov/docs/registration/canot/2022/ca2022-18.pdf>, DPR received comments requesting that DPR reevaluate, suspend, or cancel products containing paraquat dichloride. DPR received 4,683 identical or substantially similar comments submitted pursuant to an email campaign, as well as six unique comments containing references to public literature and studies. The comments expressed concern regarding human health and environmental issues regarding the use of paraquat dichloride.

In response to [California Notice 2023-12](#) (Notice), titled *Notice of Proposed Decision to Renew Pesticide Product Registrations for 2024* <cdpr.ca.gov/docs/registration/canot/2023/ca2023-12.pdf>, DPR received one comment from an environmental group again requesting that DPR reevaluate, suspend, or cancel products containing paraquat dichloride. This comment included the same public literature references submitted in 2022, as well as additional studies not referenced in the 2022 comment letters. DPR continues to evaluate the data associated with the public comments on paraquat dichloride renewal and plans to issue a response in the second half of 2024 once all available information has been considered.

For more information on this semiannual report or any of DPR's reevaluations, visit [Pesticide Registration Branch - Reevaluation Program](#) <cdpr.ca.gov/docs/registration/reevaluation/reevals.htm> or contact Mr. Taylor Whitehill, Environmental Scientist, at <Taylor.Whitehill@cdpr.ca.gov> or 916-445-2887.

Original signed by

Tulio Macedo, Chief
Pesticide Registration Branch
916-324-3527

10/04/2024

Date

cc: Mr. Taylor Whitehill, Environmental Scientist